Related Experiment Video
Updated: Dec 23, 2025

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
Published on: March 7, 2025
Lymphopenia that may develop in patients treated with temozolomide and immune control check-point inhibitor may be a
Ozgur Tanriverdi1,2,3
1Department of Medical Oncology, Faculty of Medicine, Mugla Sitki Kocman University, Mugla, Turkey. mugla.medicaloncology@gmail.com.
Abstract:
As we know more about the clinical and laboratory features of COVID-19, which is now accepted as a pandemic, many questions have been raised about how to manage and monitor the treatment of cancer patients. It was determined that the incidence of lymphopenia increased in COVID-19 and there was a significant relationship between lymphopenia and mortality. This can be thought of as an unresponsive problem in how to maintain anti-cancer drugs that cause lymphopenia. This article was written for a hypothetical approach in cancer patients diagnosed with COVID-19 in order to be an idea of collecting data for treatment with anti-cancer drugs that cause lymphopenia.
Related Concept Videos
Tumor Immunotherapy
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Immunodeficiency Diseases
There are three main causes of immunodeficiency...

